Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18871201 | USE OF AKKERMANSIA MUCINIPHILA IN PREPARATION OF PHARMACEUTICAL COMPOSITION OR HEALTH CARE PRODUCT COMPOSITION FOR IMPROVING METABOLIC SYNDROME | December 2024 | July 2025 | Allow | 7 | 1 | 0 | No | No |
| 18738464 | Probiotic Method and Composition for Maintaining a Healthy Vaginal Microbiome | June 2024 | January 2025 | Allow | 8 | 1 | 0 | Yes | No |
| 18606817 | ANTIGENIC TRIPEPTIDES DERIVED FROM MYCOBACTERIUM AVIUM SUBSP. PARATUBERCULOSIS S-TYPE STRAINS, DERIVATIVES AND USES THEREOF | March 2024 | June 2025 | Allow | 15 | 1 | 1 | No | No |
| 18605436 | GLYCOSYLATED COMP PILIN VARIANTS, METHODS OF MAKING AND USES THEREOF | March 2024 | November 2025 | Allow | 20 | 1 | 1 | No | No |
| 18601211 | COMPLEX OF BOTULINUM NEUROTOXIN E AND ITS BINDING PROTEIN AS A FORMULATION WITH ENHANCED POTENCY | March 2024 | March 2025 | Allow | 12 | 1 | 0 | Yes | No |
| 18581838 | USE OF AKKERMANSIA IN THE TREATMENT OF ORAL DISEASES | February 2024 | August 2025 | Allow | 18 | 2 | 0 | Yes | No |
| 18580997 | NOVEL LACTOBACILLUS PARACASEI ATG-E1 STRAIN OR COMPOSITION COMPRISING SAME FOR PREVENTING OR TREATING RESPIRATORY DISEASE | January 2024 | March 2026 | Allow | 26 | 1 | 0 | No | No |
| 18413961 | TREATMENT OR PREVENTION OF GASTROINTESTINAL DYSBIOSIS | January 2024 | October 2025 | Abandon | 21 | 1 | 1 | No | No |
| 18412769 | PROBIOTIC MOLECULES FOR REDUCING PATHOGEN VIRULENCE | January 2024 | July 2025 | Abandon | 18 | 1 | 1 | No | No |
| 18404430 | SILICIFIED CELL REPLICAS, METHODS OF MAKING, AND METHODS OF USING | January 2024 | June 2025 | Allow | 17 | 1 | 0 | No | No |
| 18538429 | COMBINATION THERAPIES WITH ANTI CD40 ANTIBODIES | December 2023 | October 2025 | Allow | 23 | 1 | 1 | No | No |
| 18537398 | METHODS AND MATERIALS FOR USING RUMINOCOCCUS GNAVUS OR CLOSTRIDIUM SPOROGENES TO TREAT GASTROINTESTINAL DISORDERS | December 2023 | November 2024 | Allow | 11 | 1 | 0 | No | No |
| 18535722 | TOPICAL APPLICATION TO TREAT ACNE VULGARIS | December 2023 | November 2024 | Allow | 11 | 1 | 0 | No | No |
| 18525109 | PEPTIDES DERIVED FROM ACINETOBACTER BAUMANNII AND THEIR USE IN VACCINATION | November 2023 | December 2025 | Allow | 24 | 1 | 1 | No | No |
| 18519981 | Combination Method For Treating Or Preventing Childhood Atopic Disease | November 2023 | July 2024 | Allow | 7 | 1 | 1 | No | No |
| 18508430 | BACILLUS SUBTILIS PROBIOTICS AND METHODS OF USE FOR IMPROVING IMMUNE FUNCTION, HORMONAL STATUS, AND PHYSICAL PERFORMANCE | November 2023 | March 2026 | Allow | 28 | 1 | 0 | No | No |
| 18503294 | EXPEC GLYCOCONJUGATE VACCINE FORMULATIONS | November 2023 | October 2025 | Allow | 23 | 1 | 0 | Yes | No |
| 18502728 | CELL-BASED METHOD FOR DETERMINING AN ACTIVITY OF BOTULINUM TOXIN | November 2023 | November 2024 | Abandon | 13 | 1 | 0 | No | No |
| 18467682 | Composition for Oral or Nasal Delivery of Tetanus, Diphtheria, and Pertussis Vaccine alone or in combination using Neurotoxin Associated Proteins | September 2023 | December 2024 | Allow | 15 | 1 | 0 | No | No |
| 18235686 | Method and System for Modulating an Individual's Skin Microbiome | August 2023 | January 2024 | Allow | 5 | 1 | 0 | Yes | No |
| 18234544 | Method and System for Addressing Adverse Effects on the Oral Microbiome and Restoring Gingival Health Caused by Sodium Lauryl Sulphate Exposure | August 2023 | January 2024 | Allow | 5 | 1 | 0 | No | No |
| 18234132 | Method and System to Modify an Individual's Gut-Brain Axis to Provide Neurocognitive Protection | August 2023 | January 2024 | Allow | 5 | 1 | 0 | No | No |
| 18232980 | Probiotic Composition and Method for Controlling Excess Weight, Obesity, NAFLD and NASH | August 2023 | December 2023 | Allow | 4 | 1 | 0 | No | No |
| 18446970 | MICROORGANISMS ENGINEERED TO REDUCE HYPERPHENYLALANINEMIA | August 2023 | August 2024 | Allow | 12 | 1 | 0 | No | No |
| 18269878 | BACTERIAL STRAIN BELONGING TO THE GENUS CHRISTENSENELLA, AND COMPOSITIONS | July 2023 | March 2026 | Allow | 32 | 1 | 0 | No | No |
| 18339723 | ENHANCING IMMUNOGENICITY OF STREPTOCOCCUS PNEUMONIAE POLYSACCHARIDE-PROTEIN CONJUGATES | June 2023 | January 2025 | Allow | 19 | 1 | 0 | No | No |
| 18212253 | Bifidobacterium brevis and its application in preventing or alleviating psoriasis thereof | June 2023 | January 2026 | Allow | 31 | 2 | 0 | No | No |
| 18337354 | COMPOSITION FOR THE TREATMENT OF ANTIBODY DEFICIENCIES | June 2023 | August 2024 | Allow | 14 | 1 | 0 | No | No |
| 18256430 | COMPOSITION FOR PREVENTING OR TREATING NEUROLOGICAL DISEASES OR PSYCHIATRIC DISEASES COMPRISING VESICLES DERIVED FROM SPHINGOMONAS BACTERIA | June 2023 | March 2026 | Abandon | 33 | 1 | 0 | No | No |
| 18202842 | MULTIVALENT PNEUMOCOCCAL VACCINES | May 2023 | April 2025 | Allow | 22 | 1 | 0 | No | No |
| 18320834 | GLOBAL GENE REGULATORS (GGR) AS VACCINE CANDIDATES AGAINST PARATUBERCULOSIS | May 2023 | August 2024 | Allow | 15 | 0 | 1 | No | No |
| 18319086 | COMPOSITIONS AND METHODS FOR TREATING CHOLESTATIC DISEASE | May 2023 | September 2025 | Abandon | 28 | 1 | 1 | No | No |
| 18252206 | A MYCOBACTERIUM FOR USE IN CANCER THERAPY | May 2023 | March 2026 | Allow | 34 | 1 | 0 | No | No |
| 18143399 | Modulation of an Individual's Gut Microbiome to Address Osteoporosis and Bone Disease | May 2023 | December 2023 | Allow | 7 | 2 | 0 | No | No |
| 18311691 | COMPOSITION FOR PREVENTING OR TREATING COLORECTAL CANCER COMPRISING MIXED STRAIN OF PROBIOTICS | May 2023 | October 2025 | Allow | 29 | 0 | 0 | No | No |
| 18141270 | PEPTIDES AND ANTIBODIES FOR THE REMOVAL OF BIOFILMS | April 2023 | September 2024 | Allow | 17 | 1 | 1 | No | No |
| 18305948 | Novel Polysaccharide and Uses Thereof | April 2023 | September 2024 | Allow | 17 | 1 | 1 | No | No |
| 18130946 | Probiotic to Enhance an Individual's Skin Microbiome | April 2023 | July 2023 | Allow | 4 | 1 | 0 | Yes | No |
| 18129791 | System And Method For The Detection And Prevention of Leukemia And Lymphoma | March 2023 | July 2024 | Allow | 15 | 2 | 1 | Yes | No |
| 18178847 | Topical Application of CRISPR-Modified Bacteria to Treat Acne Vulgaris | March 2023 | July 2023 | Allow | 5 | 1 | 0 | No | No |
| 18184869 | Tuberculosis Antigen Cassettes | March 2023 | July 2024 | Allow | 17 | 1 | 0 | No | No |
| 18184711 | BACILLUS BACTERIUM, INTERLEUKIN-22 PRODUCTION INDUCING AGENT, SKIN BARRIER FUNCTION ENHANCING AGENT | March 2023 | December 2024 | Allow | 21 | 2 | 0 | Yes | No |
| 18044728 | CONJUGATE AND PHOTOIMMUNOTHERAPY | March 2023 | January 2026 | Allow | 35 | 1 | 0 | Yes | No |
| 18178602 | VACCINATION AGAINST DIABETES, OBESITY AND COMPLICATIONS THEREOF | March 2023 | February 2026 | Abandon | 36 | 0 | 1 | No | No |
| 18022763 | USE OF ADLERCREUTZIA BACTERIA FOR THE TREATMENT OF INFLAMMATORY DISEASES | February 2023 | January 2026 | Allow | 35 | 1 | 0 | No | No |
| 18019383 | RECOMBINANT BACTERIA FOR PRODUCTION OF D-LACTATE AND/OR L-LACTATE AND USES THEREOF | February 2023 | December 2025 | Abandon | 34 | 0 | 1 | No | No |
| 18103768 | Method and System to Reduce the Likelihood of Dental Caries and Halitosis | January 2023 | July 2023 | Allow | 6 | 1 | 0 | No | No |
| 18040079 | PROBIOTIC SYSTEM AND USE THEREOF | January 2023 | November 2025 | Allow | 34 | 1 | 1 | Yes | No |
| 18158047 | Methods and Compositions for Treatment of Microbiome Associated Disorders | January 2023 | July 2024 | Allow | 18 | 1 | 0 | No | No |
| 18017307 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING ATOPIC DISEASE CONTAINING FAECALIBACTERIUM PRAUSNITZII STRAIN | January 2023 | February 2026 | Allow | 36 | 2 | 0 | Yes | No |
| 18151205 | Compositions and Methods for the Treatment of Hepatic Diseases and Disorders | January 2023 | February 2025 | Allow | 26 | 1 | 1 | No | No |
| 18146783 | HYBRIDOMA CELL LINE OF SECRETING CYPROHEPTADINE MONOCLONAL ANTIBODIES AND PREPARATION METHOD THEREOF | December 2022 | December 2024 | Allow | 24 | 3 | 0 | Yes | No |
| 18087545 | Topical Application of Lactobacillus Crispatus to Ameliorate Barrier Damage and Inflammation | December 2022 | July 2023 | Allow | 7 | 1 | 0 | Yes | No |
| 18003012 | ANTI-PD1 ANTIBODIES AND USES THEREOF | December 2022 | March 2026 | Abandon | 38 | 1 | 0 | No | No |
| 18069535 | BOTULINUM NEUROTOXIN FOR TREATMENT OF DISORDERS ASSOCIATED WITH MELANOCYTE HYPERACTIVITY AND/OR EXCESS MELANIN | December 2022 | November 2025 | Abandon | 35 | 1 | 0 | No | No |
| 18010170 | TREATMENT OF FOOD ALLERGY USING ANTI-IGE ANTIBODIES | December 2022 | February 2026 | Abandon | 38 | 1 | 0 | No | No |
| 17913749 | MODIFIED CHANNELRHODOPSIN | December 2022 | August 2025 | Allow | 34 | 1 | 0 | No | No |
| 18073824 | TREATMENT OF SEVERE COMMUNITY ACQUIRED PNEUMONIA | December 2022 | August 2024 | Allow | 21 | 1 | 0 | No | No |
| 18074122 | BACTERIAL EXTRACELLULAR VESICLES | December 2022 | May 2024 | Allow | 18 | 1 | 0 | No | No |
| 18072841 | LIQUID PHARMACEUTICAL COMPOSITION | December 2022 | June 2024 | Abandon | 19 | 0 | 1 | No | No |
| 18072852 | LIQUID PHARMACEUTICAL COMPOSITION | December 2022 | November 2024 | Abandon | 24 | 1 | 0 | No | No |
| 18057957 | MDR E. COLI IMMUNOGEN | November 2022 | December 2024 | Allow | 25 | 2 | 2 | Yes | No |
| 17982067 | FASTING-MIMICKING DIET (FMD) BUT NOT WATER-ONLY FASTING PROMOTES REVERSAL OF INFLAMMATION AND IBD PATHOLOGY | November 2022 | August 2024 | Allow | 22 | 1 | 1 | No | No |
| 17981262 | CHROMATOGRAPHY LIGAND COMPRISING DOMAIN C FROM STAPHYLOCOCCUS AUREUS PROTEIN A FOR ANTIBODY ISOLATION | November 2022 | February 2025 | Allow | 28 | 2 | 0 | No | No |
| 17922960 | METHODS FOR DIAGNOSING AND TREATING METABOLIC DISEASES | November 2022 | October 2025 | Abandon | 36 | 0 | 1 | No | No |
| 17922499 | LIVE SELF-DESTRUCTING BACTERIAL ADJUVANTS TO ENHANCE INDUCTION OF IMMUNITY | October 2022 | December 2025 | Allow | 37 | 1 | 1 | No | No |
| 18048631 | DONOR REPAIR TEMPLATES MULTIPLEX GENOME EDITING | October 2022 | October 2025 | Allow | 36 | 1 | 0 | No | No |
| 17996720 | COMPOSITION FOR USE IN THE TREATMENT OF GROUP-B STREPTOCOCCUS (GBS) INFECTIONS | October 2022 | September 2025 | Allow | 35 | 1 | 0 | No | No |
| 17996779 | COMPOSITIONS AND METHODS COMPRISING CLOSTRIDIUM BUTYRICUM FOR THE TREATMENT OF CANCER | October 2022 | December 2025 | Allow | 37 | 1 | 1 | No | No |
| 17919734 | A NANO-ENABLED VACCINATION APPROACH FOR CORONAVIRUS DISEASE (COVID-19) AND OTHER VIRAL DISEASES | October 2022 | February 2026 | Abandon | 40 | 0 | 1 | No | No |
| 17938865 | ANTIGENIC TRIPEPTIDES DERIVED FROM MYCOBACTERIUM AVIUM SUBSP. PARATUBERCULOSIS S-TYPE STRAINS, DERIVATIVES AND USES THEREOF | October 2022 | January 2024 | Allow | 15 | 0 | 0 | No | No |
| 17917531 | CHARGE VARIANT LINKERS | October 2022 | January 2026 | Abandon | 40 | 0 | 1 | No | No |
| 17937819 | COMBINATION THERAPY FOR TREATING OR PREVENTING CANCER | October 2022 | April 2024 | Abandon | 18 | 1 | 0 | No | No |
| 17952990 | TARS DERIVED FROM AKKERMANSIA MUCINIPHILA OR FRAGMENT THEREOF, AND USE THEREOF | September 2022 | February 2026 | Allow | 40 | 1 | 1 | No | No |
| 17907054 | USE OF BY-PRODUCTS FROM THE ALCOHOLIC BEVERAGE MANUFACTURING INDUSTRY | September 2022 | November 2025 | Allow | 38 | 1 | 0 | Yes | No |
| 17910975 | SHEDDING BLOCKING AGENTS WITH INCREASED STABILITY | September 2022 | December 2025 | Allow | 39 | 1 | 0 | No | No |
| 17909917 | A VACCINE FOR PROTECTION AGAINST STREPTOCOCCUS SUIS SEROTYPE 9, SEQUENCE TYPE 16 | September 2022 | April 2025 | Allow | 31 | 0 | 1 | No | No |
| 17908703 | CHIMERIC ANTIGEN RECEPTORS AND RELATED METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | September 2022 | November 2025 | Allow | 39 | 1 | 0 | No | No |
| 17904998 | DIGESTIVE ENZYME AGENT | August 2022 | February 2026 | Abandon | 42 | 1 | 0 | No | No |
| 17905001 | COMPOSITIONS AND METHODS FOR REDUCING CYTOKINE EXPRESSION | August 2022 | September 2025 | Abandon | 37 | 1 | 0 | No | No |
| 17893384 | Method and System for Reducing the Likelihood of Osteoporosis | August 2022 | August 2023 | Allow | 12 | 1 | 0 | Yes | No |
| 17801786 | NOVEL ANTIBODIES | August 2022 | December 2025 | Allow | 40 | 0 | 1 | No | No |
| 17820252 | COMPOSITIONS COMPRISING BACTERIAL STRAINS | August 2022 | May 2024 | Abandon | 21 | 0 | 1 | No | No |
| 17820029 | METHODS FOR TREATING AND FOR INHIBITING PROGRESSION OF SEIZURES | August 2022 | December 2025 | Abandon | 40 | 1 | 0 | No | No |
| 17798420 | CUTIBACTERIUM ACNES STRAIN AND MEDICAL USES THEREOF | August 2022 | August 2025 | Allow | 37 | 1 | 0 | No | No |
| 17879700 | COMPOSITION FOR USE IN THE TREATMENT AND/OR IMPROVEMENT OF SLEEP AND MOOD DISORDERS | August 2022 | October 2023 | Allow | 15 | 1 | 0 | No | No |
| 17815705 | BIOCONJUGATES OF E. COLI O-ANTIGEN POLYSACCHARIDES, METHODS OF PRODUCTION THEREOF, AND METHODS OF USE THEREOF | July 2022 | October 2023 | Allow | 15 | 0 | 0 | No | No |
| 17874846 | Capture Purification Processes for Proteins Expressed in a Non-Mammalian System | July 2022 | January 2025 | Allow | 30 | 1 | 0 | No | No |
| 17758379 | METHODS FOR IDENTIFYING ANTI CLOSTRIDIAL NEUROTOXIN COMPOUNDS | July 2022 | October 2025 | Allow | 40 | 0 | 1 | Yes | No |
| 17857614 | LOCALIZED IMMUNOSUPPRESSION OF ALLOGRAFTS FOR PERIPHERAL NERVE REPAIR | July 2022 | April 2025 | Allow | 34 | 0 | 0 | No | No |
| 17856013 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF C. DIFFICILE | July 2022 | September 2023 | Allow | 15 | 0 | 0 | No | No |
| 17854422 | Method for Treating Individuals Having Cancer and who are Receiving Cancer Immunotherapy | June 2022 | February 2023 | Allow | 8 | 2 | 0 | No | No |
| 17853134 | Anti-TIGIT Antibodies | June 2022 | January 2024 | Abandon | 18 | 0 | 1 | No | No |
| 17850422 | VACCINE TO PREVENT MYCOPLASMAL INFECTIONS IN WATERFOWL | June 2022 | February 2024 | Allow | 20 | 0 | 0 | No | No |
| 17848759 | Method for Treating an Individual Suffering from Bladder Cancer | June 2022 | December 2022 | Allow | 6 | 1 | 0 | No | No |
| 17835204 | Method and System for Reducing the Likelihood of Developing Colorectal Cancer in an Individual Human Being | June 2022 | August 2022 | Allow | 2 | 1 | 0 | No | No |
| 17832487 | MICROORGANISMS ENGINEERED TO REDUCE HYPERPHENYLALANINEMIA | June 2022 | June 2023 | Allow | 13 | 1 | 1 | Yes | No |
| 17664156 | ALTERING THE INTESTINAL MICROBIOME IN CYSTIC FIBROSIS | May 2022 | October 2024 | Allow | 29 | 2 | 0 | No | No |
| 17737513 | Compositions and Methods for Treating the Eye | May 2022 | September 2023 | Allow | 16 | 1 | 0 | No | No |
| 17727129 | MICROBIAL CONSORTIA | April 2022 | June 2024 | Abandon | 26 | 0 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner GANGLE, BRIAN J.
With a 12.5% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 10.7% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner GANGLE, BRIAN J works in Art Unit 1645 and has examined 1,020 patent applications in our dataset. With an allowance rate of 70.8%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 27 months.
Examiner GANGLE, BRIAN J's allowance rate of 70.8% places them in the 33% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by GANGLE, BRIAN J receive 1.68 office actions before reaching final disposition. This places the examiner in the 34% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by GANGLE, BRIAN J is 27 months. This places the examiner in the 71% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.
Conducting an examiner interview provides a +21.9% benefit to allowance rate for applications examined by GANGLE, BRIAN J. This interview benefit is in the 67% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 26.4% of applications are subsequently allowed. This success rate is in the 43% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 64.0% of cases where such amendments are filed. This entry rate is in the 88% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 1% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.
This examiner withdraws rejections or reopens prosecution in 73.3% of appeals filed. This is in the 62% percentile among all examiners. Of these withdrawals, 81.8% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 62.2% are granted (fully or in part). This grant rate is in the 67% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 6.1% of allowed cases (in the 88% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 4.4% of allowed cases (in the 79% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.